Relpax Adverse Reactions

RELPAX has been administered in clinical trials to more than 5,000 patients.
Eletriptan is generally well tolerated. Adverse reactions were usually transient and mild to moderate in nature and resolved spontaneously without additional treatment. The incidence and severity of adverse events seen in patients who took two doses of the same strength to treat a single attack were similar to these observed in patients who only took one dose.
The following adverse reactions (with an incidence ≥1% and higher than placebo) were reported in patients treated with therapeutic doses in clinical trials: Nervous System Disorders: Common: Dizziness, headache, hypertonia, hypoesthesia, myasthenia, paraesthesia, somnolence.
Ear and Labyrinth Disorders: Common: Vertigo.
Cardiac Disorders: Common: Palpitation, tachycardia.
Vascular Disorders: Common: Sensation of warmth or flushing.
Respiratory, Thoracic and Mediastinal Disorders: Common: Pharyngitis, throat tightness.
Gastrointestinal Disorders: Common: Abdominal pain, dry mouth, dyspepsia, nausea.
Skin and Subcutaneous Tissue Disorders: Common: Sweating.
Musculoskeletal, Connective Tissue and Bone Disorders: Common: Back pain, myalgia.
General Disorders and Administration Site Conditions: Common: Asthenia, chest symptoms (pain, tightness, pressure), chills, pain.
The common adverse events seen with eletriptan are typical of adverse events reported with 5-HT₁ agonists as a class.
In post-marketing experience, the following additional undesirable effects have been reported: Immune System Disorders: Allergic reaction, some of which may be serious, including angioedema.
Nervous System Disorders: Rare cases of syncope.
Vascular: Hypertension.
Gastrointestinal Disorders: Vomiting, rare cases of ischaemic colitis.
Cardiac Disorders: Myocardial ischemia or infarction, arteriospasm coronary.
Skin and Subcutaneous Tissue Disorders: Pruritus, rash, urticaria.